Elevated concentrations of Nη-homocysteinyl-lysine isopeptide in acute myocardial infarction: Links with ADMA formation

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 4, 2011, Pages 729-735

  Za̧bczyk, Michal ^a   Gløwacki, Rafal ^b   MacHnik, Andrzej ^c   Heród, Pawel ^c   Kazek, Grzegorz ^a   Jakubowski, Hieronim ^d,e,f   Undas, Anetta ^a,c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^d INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^e POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

acute myocardial infarction; asymmetric dimethylarginine; homocysteine; N

Indexed keywords

6 N,N' DIMETHYLARGININE; 8 ISOPROSTAGLANDIN F2 ALPHA; AMINO ACID; AUTOANTIBODY; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; GLUTATHIONE; HOMOCYSTEINE; INTERLEUKIN 6; N EPSILON HOMOCYSTEINYL LYSINE; N(G),N(G) DIMETHYLARGININE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; UNCLASSIFIED DRUG; ARGININE; DIPEPTIDE; DRUG DERIVATIVE; N(EPSILON) HOMOCYSTEINYL LYSINE; N(EPSILON)-HOMOCYSTEINYL-LYSINE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; FEMALE; FIBRINOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; THORAX PAIN; BIOSYNTHESIS; BLOOD; ENDOTHELIUM; HEART INFARCTION; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

NETA;

ARGININE; AUTOANTIBODIES; DIPEPTIDES; ENDOTHELIUM; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; THROMBIN;

EID: 79954538856     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.107     Document Type: Article

References (30)

1. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002;325:1202.
2. Ebbing M, Bønaa KH, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, et al. Combined analyses and extended follow-up oftwo randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med 2010;268:367-82.
3. Mudd SH, Levy HL, Krauss JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The meta-bolic and molecular bases of inherited disease. Vol. 2, 8th ed. New York: McGraw-Hill, 2001:2007-56.
4. Jakubowski H, Goldman E. Synthesis of homocysteine thiolac-tone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett 1993;317:237-40. (Pubitemid 23045796)
5. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999;13:2277-83.
6. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological con-sequences of elevated homocysteine levels. J Biol Chem 1997; 272:1935-42. (Pubitemid 27043288)
7. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000;130(Suppl): S377-81.
8. Jakubowski H. Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease. J Biol Chem 2002;277:30425-8. (Pubitemid 34970732)
9. Jakubowski H. New method for the determination of protein N-linked homocysteine. Anal Biochem 2008;380:257-61.
10. Jakubowski H, Boers GH, Strauss KA. Mutations in cystathio-nine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB J 2008;22:4071-6.
11. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 2004;61:470-87. (Pubitemid 38316582)
12. Jakubowski H. The molecular basis of homocysteine thiolac-tone-mediated vascular disease. Clin Chem Lab Med 2007;45: 1704-16. (Pubitemid 350232966)
13. Jakubowski H. The pathophysiological hypothesis of homocys-teine thiolactone-mediated vascular disease. J Physiol Phar-macol 2008;59(Suppl 9):S155-67.
14. Jakubowski H. Anti-N-homocysteinylated protein autoantibod-ies and cardiovascular disease. Clin Chem Lab Med 2005;43: 1011-4. (Pubitemid 41581953)
15. Undas A, Perla J, Lacinski M, Trzeciak W, Kazmierski R, Jaku-bowski H. Autoantibodies against N-homocysteinylated pro-teins in humans: implications for atherosclerosis. Stroke 2004;35:1299-304. (Pubitemid 38697447)
16. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study Atherosclerosis 2007;191: 206-10. (Pubitemid 46227419)
17. Lentz SR. Mechanisms of homocysteine-induced atherothrom-bosis. J Thromb Haemost 2005;3:1646-54.
18. Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med 2005;10(Suppl 1):S27-33. (Pubitemid 43137265)
19. Stühlinger MC, Oka RK, Graf EE, Schmölzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperho-mocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933-8. (Pubitemid 37048221)
20. Glowacki R, Bald E, Jakubowski H. Identification and origin of Nepsilon-homocysteinyl-lysine isopeptide in humans and mice. Amino Acids 2010.
21. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38. (Pubitemid 47616190)
22. Glowacki R, Bald E. Fully automated method for simultaneous determination of total cysteine, cysteinylglycine, glutathione and homocysteine in plasma by HPLC with UV absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3400-4.
23. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Deter-mination of arginine, asymmetric dimethylarginine, and sym-metric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography Anal Biochem 2002;303:131-7. (Pubitemid 34407576)
24. Undas A, Stepien E, Glowacki R, Tisonczyk J, Tracz W, Jaku-bowski H. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocystei-nemia. Thromb Haemost 2006;96:342-7. (Pubitemid 44377819)
25. Korandji C, Zeller M, Guilland JC, Vergely C, Sicard P, Duvil-lard L, et al. Asymmetric dimethylarginine (ADMA) and hyper-homocysteinemia in patients with acute myocardial infarction. Clin Biochem 2007;40:66-72. (Pubitemid 46019878)
26. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tya-gi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 2005;289:2649-56.
27. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dime-thylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119:1533-40. (Pubitemid 27019525)
28. Zhang JG, Wang LZ, Han XQ, Jiang YD, Zhang RM, Wang SR. [The pathogenic mechanism of homocysteine-induced endothelial nitric oxide synthase dysfunction and the antago-nistic effects by folic acid]. Fen Zi Xi Bao Sheng Wu Xue Bao 2007;40:17-23.
29. Undas A, Jankowski M, Twardowska M, Padjas A, Jakubowski H, Szczeklik A. Antibodies to N-homocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb Haemost 2005;93:346-50. (Pubitemid 40253742)
30. Padjas A, Undas A, Swadzba J, Musial J. [Antibodies to N-homocysteinylated albumin in patients with systemic lupus ery-thematosus]. Pol Arch Med Wewn 2007;117:20-5. (Pubitemid 46997745)